ROIV
Next earnings: May 28, 2026 · Before open
Signal
Leaning Bullish1
Price
1
Move+0.68%Quiet session
Volume
1
Volume0.1× avgLight volume
Technical
1
RSIRSI 57Momentum positive
PRICE
Prev Close
27.83
Open
28.48
Day Range27.56 – 28.48
27.56
28.48
52W Range10.58 – 30.33
10.58
30.33
88% of range
VOLUME & SIZE
Avg Volume
6.1M
FUNDAMENTALS
P/E Ratio
-23.9x
Not profitable
EPS (TTM)
Div Yield
No dividend
Beta
1.04
Market-like
Quick Read
TrendInsufficient MA data
Momentum
NEUTRAL
rev -56% · 91% gross margin
Valuation
FAIR
P/E not available
Health
MODERATE
CR 30.7 · FCF negative
Lean Bullish
Key MetricsTTM
Market Cap$19.99B
Revenue TTM$13.31M
Net Income TTM-$809.24M
Free Cash Flow-$766.86M
Gross Margin91.2%
Net Margin-6079.9%
Operating Margin-9130.5%
Return on Equity-18.3%
Return on Assets-15.5%
Debt / Equity0.05
Current Ratio30.66
EPS TTM$-1.16

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
3 strong3 concern
50/100
Liquidity
30.66Strong
Leverage
0.05Strong
Coverage
0.0xConcern
ROE
-18.3%Concern
ROIC
-23.9%Concern
Cash
$2.7BStrong
ANALYST COVERAGE14 analysts
BUY
+14.2%upside to target
L $30.00
Med $32.00consensus
H $40.00
Buy
1393%
Hold
17%
13 Buy (93%)1 Hold (7%)0 Sell (0%)
Full report →
Stock Health
Composite Score
4 of 4 signals bullish
10/10
Technicals
RSI RangeRSI 57 — Bullish momentum
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 30.66 — healthy liquidity

1 signal unavailable — limited data for this stock

Upcoming Events
EEarnings ReportMay 5, 2026
Tomorrow
DEx-Dividend DateAug 2, 2026
In 90 days
Technicals
Technical SetupBULLISH
Technicals →

Trend

UptrendGolden Cross · 50D leads 200D by 54.7%

+36.1% vs SMA 50 · +110.5% vs SMA 200

Momentum

RSI57.1
Positive momentum, not extended
MACD+1.36
Above zero — bullish momentum · expanding
Market Position
Price Levels
52W High
$30.33+8.2%
Current
$28.02
EMA 50
$20.53-26.7%
EMA 200
$13.31-52.5%
52W Low
$10.58-62.2%
52-Week RangeNear 52-week high
$10.5888th %ile$30.33
Earnings & Analysts

ANALYST ESTIMATES

Consensus of 9 analysts
Analyst revisions:EPS↑ Revised UpRevenue↑ Revised Up

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$141.4M
$86.5M$214.1M
-$0.52
±5%
High5
FY2026(current)
$9.1M
$4.6M$20.1M
-93.6%-$1.12
±50%
High9
FY2027
$76.0M
$8.4M$238.5M
+736.0%-$1.18
±5%
High9
Range confidence:Tight (high)ModerateWide (low)
🔥Beat 5 consecutive quarters
Earnings HistoryROIV
Last 8Q
+18.0%avg beat
Beat 7 of 8 quartersMissed 1 Estimates falling
+13%
Q2'24
+26%
Q3'24
-17%
Q4'24
+46%
Q1'25
+17%
Q2'25
+28%
Q3'25
+12%
Q4'25
+20%
Q1'26
Beat
Miss
Estimate
Deeper color = bigger beat/miss
* Negative EPS shown at reduced height
Insider Activity
SEC Filings →
0 Buys/6 SellsNet Selling
NET SELLERS$0 bought · $14.8M sold · 30d window
Venker EricPresident & Im…
$5.9M
Apr 20
SELL
Gline MatthewDir
$8.4M
Apr 16
SELL
Humes JenniferChief Accounti…
$384K
Apr 8
SELL
Fitzgerald MeghanDir
$1.9M
Mar 26
SELL
Venker EricPresident & Im…
$5.6M
Mar 17
SELL
Epperly Melissa B,Dir
$1.2M
Mar 16
SELL
Financials

INSTITUTIONAL OWNERSHIP

1
Assenagon Asset Management S.A.
7.1M
2
Pictet Asset Management Holding SA
2.7M
3
Candriam S.C.A.
2.0M
4
Nuveen, LLC
2.0M
5
PENN DAVIS MCFARLAND INC
1.6M
6
SG Americas Securities, LLC
641K
7
Retirement Systems of Alabama
553K
8
Consolidated Portfolio Review Corp
277K
News & Activity

ROIV News

20 articles · 4h ago

About

roivant is a global healthcare company focused on rapidly developing innovative medicines. we believe that the key to unlocking innovation in drug discovery and drug commercialization is to reduce the time and cost of the drug development process. we solve this problem by building vants – nimble, entrepreneurial biotech companies with a unique approach to sourcing talent, aligning economic incentives, and deploying technology to drive greater efficiency in pharma r&d; and commercialization. the goal of our model is to ensure that important medicines rapidly reach patients who suffer from serious diseases. we focus on disease areas where the magnitude of r&d; investment from industry is disproportionately low relative to societal medical needs. we also launch new vants to directly improve the process of developing and commercializing new medicines. our pipeline spans multiple therapeutic areas through partnerships with academic institutions and biopharmaceutical companies, including tak

Industry
Research and Development in Biotechnology (except Nanobiotechnology)
CEO
Matthew Gline
Country
UK
Frank TortiPresident & Vant Chair
Mayukh SukhatmePresident, Chief Investment Officer & Director
Eric VenkerPresident & Chief Executive Officer of Immunovant